Biotherapeutics Inc. (BTI) is a science-based biotechnology company organized around integrating nutraceuticals, pharmaceuticals and informatics to advance precision medicine for preventing and treating autoimmune and metabolic diseases. Initiated by a Virginia Tech professor - also director of the universitys Nutritional Immunology and Molecular Medicine Laboratory (NIMML) - BioTherapeutics, Inc. BTI was established to make the shift from research to product-in-use, and to demonstrate the value of the university-industry link by developing BT-11, an orally active, first-in-class therapeutic for Crohns Disease (CD) and abscisic acid (ABA), a food ingredient for glycemic control. BioTherapeutics is focused on synergistically combining the power of advanced computational modeling with translational experimentation to accelerate the development of innovative products for personalized nutrition and health. The firm has animportant collaboration with the Spanish firm Euromed to launch an abscisic acid nutritional ingredient to market
